Union européenne - maltais - EMA (European Medicines Agency)

gilead sciences international limited - cidofovir - cytomegalovirus retinite - antivirali għal użu sistemiku - vistide huwa indikat għall-kura ta 'retinite b'cytomegalovirus f'pazjenti b'sindromu ta' immunodefiċjenza miksuba (aids) u mingħajr disfunzjoni tal-kliewi. vistide għandu jintuża biss meta aġenti oħra huma kkunsidrati bħala mhux adattati.

Union européenne - maltais - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - glecaprevir, pibrentasvir - epatite Ċ, kronika - antivirali għal użu sistemiku - maviret is indicated for the treatment of chronic hepatitis c virus (hcv) infection in adults and children aged 3 years and older. maviret coated granules is indicated for the treatment of chronic hepatitis c virus (hcv) infection in children 3 years and older.

Union européenne - maltais - EMA (European Medicines Agency)

eurocept international bv - karglumic acid - hyperammonemia; amino acid metabolism, inborn errors - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - ucedane is indicated in treatment of:hyperammonaemia due to n-acetylglutamate synthase primary deficiency;hyperammonaemia due to isovaleric acidaemia;hyperammonaemia due to methymalonic acidaemia;hyperammonaemia due to propionic acidaemia.

Union européenne - maltais - EMA (European Medicines Agency)

accord healthcare s.l.u. - entecavir - epatite b, kronika - antivirali għal użu sistemiku - entecavir accord is indicated for the treatment of chronic hepatitis b virus (hbv) infection in adults with: , compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (alt) levels and histological evidence of active inflammation and/or fibrosis. , mard tal-fwied dekompensat. , kemm għall-kkumpensati u mard tal-fwied dikumpensat, din l-indikazzjoni hija bbażata fuq tagħrif minn provi kliniċi f'pazjenti li huma nucleoside naïve b'hbeag pożittiv u hbeag negattiv li jaqbadhom infezzjoni hbv. fir-rigward ta 'pazjenti b'epatite b refrattarja għal lamivudine. entecavir-ftehim huwa indikat ukoll għat-trattament ta ' infezzjoni hbv kronika nucleoside naïve pazjenti pedjatriċi minn 2 sa.

Union européenne - maltais - EMA (European Medicines Agency)

mylan s.a.s - ritonavir - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - ritonavir huwa indikat flimkien ma 'aġenti antiretrovirali oħra għat-trattament ta' pazjenti infettati bl-hiv 1 (adulti u tfal ta '2 snin u aktar).

Union européenne - maltais - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir, kobikistat, emtricitabine, tenofovir alafenamide - infezzjonijiet ta 'hiv - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - symtuza huwa indikat għat-trattament tal-virus ta ' immunodefiċjenza umani tat-tip 1 (hiv‑1) infezzjoni fl-adulti u l-adolexxenti (età 12-il sena u aktar antiki mal-korp tal-mill-inqas 40 kg piż). genotypic testing should guide the use of symtuza.

Union européenne - maltais - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir, velpatasvir, voxilaprevi - epatite Ċ, kronika - antivirali għal użu sistemiku - vosevi is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients aged 12 years and older and weighing at least 30 kg. (ara sezzjonijiet 4. 2, 4. 4 u 5.

Union européenne - maltais - EMA (European Medicines Agency)

viiv healthcare b.v. - dolutegravir tas-sodju, rilpivirina hydrochloride - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - juluca huwa indikat għall-kura tal-vajrus tal-immunodefiċjenza umana tat-tip 1 (hiv-1) f'adulti li huma viroloġikament-mrażżna (hiv-1 rna.

Union européenne - maltais - EMA (European Medicines Agency)

atnahs pharma netherlands b.v. - macimorelin acetate - tekniki dijanjostiċi, endokrinali - macimorelin - dan il-prodott mediċinali huwa għal użu dijanjostiku biss.  ghryvelin is indicated for the diagnosis of growth hormone deficiency (ghd) in adults.

Union européenne - maltais - EMA (European Medicines Agency)

accord healthcare s.l.u. - posaconazole - mikosijiet - antimikotiċi għal użu sistemiku - posaconazole accord is indicated for use in the treatment of the following fungal infections in adults:invasive aspergillosis;fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. ir-refrattorjetà hija definita bħala l-progressjoni tal-infezzjoni jew nuqqas ta 'titjib wara minimu ta' 7 ijiem ta 'dożi terapewtiċi preċedenti ta' terapija antifungali effettiva. posaconazole qbil huwa indikat ukoll għal profilassi ta 'infezzjonijiet fungali invażivi fil-pazjenti li ġejjin: pazjenti li kienu qed jirċievu remissjoni-induzzjoni ta' kimoterapija għal lewkimja majeloġenuża akuta (aml) jew għal sindromi majelodisplastiċi (mds) mistennija li jikkawżaw newtropenja u li huma f'riskju għoli li jiżviluppaw infezzjonijiet tal-fungu invażivi;trapjant ta'ċelloli staminali ematopojetiċi (hsct) riċevituri li huma għaddejjin minn doża għolja ta ' terapija immunosopprimenti għal-graft kontra l-host u li huma f'riskju għoli li jiżviluppaw infezzjonijiet invażivi tal-fungu.